DexCom Inc. [DXCM] moved down -7.87: Why It’s Important

DexCom Inc. [NASDAQ: DXCM] closed the trading session at $113.25 on 03/06/23. The day’s price range saw the stock hit a low of $112.44, while the highest price level was $116.079. The company report on February 28, 2023 that What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


DarioHealth (NASDAQ: DRIO) Partners With Dexcom (NASDAQ: DXCM) The Global Leader in Continuous Glucose Monitoring (CGM) To Integrate Dario’s Multi-Chronic Condition Platform.

The stocks have a year to date performance of 0.01 percent and weekly performance of 2.41 percent. The stock has been moved at 36.31 percent over the last six months. The stock has performed 4.83 percent around the most recent 30 days and changed -4.05 percent over the most recent 3-months.

If compared to the average trading volume of 2.62M shares, DXCM reached to a volume of 5555340 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about DexCom Inc. [DXCM]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DXCM shares is $132.74 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DXCM stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for DexCom Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 26, 2023. While these analysts kept the previous recommendation, Barclays raised their target price to Equal Weight. The new note on the price target was released on October 18, 2022, representing the official price target for DexCom Inc. stock. Previously, the target price had yet another raise to $125, while Jefferies analysts kept a Buy rating on DXCM stock.

The Average True Range (ATR) for DexCom Inc. is set at 4.59, with the Price to Sales ratio for DXCM stock in the period of the last 12 months amounting to 14.83. The Price to Book ratio for the last quarter was 20.52, with the Price to Cash per share for the same quarter was set at 6.44. Price to Free Cash Flow for DXCM in the course of the last twelve months was 141.66 with Quick ratio for the last quarter at 1.80.

DXCM stock trade performance evaluation

DexCom Inc. [DXCM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.41. With this latest performance, DXCM shares gained by 4.83% in over the last four-week period, additionally plugging by 36.31% over the last 6 months – not to mention a rise of 6.85% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DXCM stock in for the last two-week period is set at 50.19, with the RSI for the last a single of trading hit 48.49, and the three-weeks RSI is set at 50.84 for DexCom Inc. [DXCM]. The present Moving Average for the last 50 days of trading for this stock 111.17, while it was recorded at 115.84 for the last single week of trading, and 96.63 for the last 200 days.

DexCom Inc. [DXCM]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and DexCom Inc. [DXCM] shares currently have an operating margin of +13.44 and a Gross Margin at +64.46. DexCom Inc.’s Net Margin is presently recorded at +11.73.

Return on Equity for this stock inclined to 15.57, with Return on Assets sitting at 6.65.

DexCom Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.00.

Earnings per share (EPS) analysis for DexCom Inc. [DXCM] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DXCM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for DexCom Inc. go to 30.60%.

DexCom Inc. [DXCM]: Insider Ownership positions

There are presently around $42,088 million, or 98.80% of DXCM stock, in the hands of institutional investors. The top three institutional holders of DXCM stocks are: VANGUARD GROUP INC with ownership of 43,819,836, which is approximately 0.315% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 33,189,893 shares of the stock with an approximate value of $3.76 billion in DXCM stocks shares; and BAILLIE GIFFORD & CO, currently with $1.96 billion in DXCM stock with ownership of nearly -4.431% of the company’s market capitalization.

Positions in DexCom Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 506 institutional holders increased their position in DexCom Inc. [NASDAQ:DXCM] by around 27,598,962 shares. Additionally, 364 investors decreased positions by around 25,940,350 shares, while 95 investors held positions by with 318,101,133 shares. The mentioned changes placed institutional holdings at 371,640,445 shares, according to the latest SEC report filing. DXCM stock had 171 new institutional investments in for a total of 4,393,960 shares, while 48 institutional investors sold positions of 489,719 shares during the same period.


Please enter your comment!
Please enter your name here